epirubicin + cyclophosphamide + docetaxel + bevacizumab

This is a combination regimen consisting of four drugs: - Epirubicin, an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to inhibition of DNA replication and RNA synthesis. - Cyclophosphamide, an alkylating agent that crosslinks DNA strands, preventing cell division and causing cell death. - Docetaxel, a taxane-class chemotherapeutic that stabilizes microtubules and prevents their depolymerization, thereby inhibiting mitosis. - Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), which inhibits angiogenesis by blocking the formation of new blood vessels necessary for tumor growth[3][4][5][6]. This combination is used in oncology clinical trials for the treatment of various cancers—most notably breast cancer—where it leverages both cytotoxic chemotherapy (epirubicin, cyclophosphamide, docetaxel) and targeted antiangiogenic therapy (bevacizumab)[5][6]. The regimen aims to maximize tumor cell kill while also disrupting the tumor’s blood supply.